500 new Diagnostics jobs in Scotland at expanded global research hub
£78 million investment at three Scottish sites by LumiraDx to grow total local employment to more than 1,000 by 2023
More than 500 new jobs are to be created in Scotland under plans by life sciences giant LumiraDx to establish a global health research, development and manufacturing hub.
The advanced diagnostics company has unveiled a £78 million investment in its current Scottish operations which could see the number of new jobs created over the next three years eventually reach 750.
The new jobs will be created at numerous sites across the country, including new facilities being prepared at Eurocentral near Glasgow. About 200 of the new roles will be in research and development (R&D), with the rest in high-tech manufacturing.
The expansion is likely to more than double the firm's existing workforce in Scotland of 579.
LumiraDx has developed a next generation point of care diagnostic platform and tests including its high sensitivity antigen test for COVID-19 which is currently being used by the NHS in Scotland. The LumiraDx Platform menu also includes point of care tests for COVID-19 Antibody, INR and D-Dimer – all commercially available in Europe. The platform is designed to go wherever the patient is, whether this is in a hospital, GP surgery, pharmacy, or in other non-traditional settings such as schools or airports.
The new jobs in Scotland will further support scale-up of current COVID-19 antigen test manufacturing as well as the development of other groundbreaking point of care tests. The company currently has a pipeline of 30 tests for conditions including blood clots, heart disease, and diabetes.
A total of 510 new posts will be guaranteed over the next three years as a result of the fresh investment which includes £15 million of grant support provided by Scottish Enterprise. The firm is hopeful this could rise to more than 750 new posts if current market demands prevail.
Economy Secretary Fiona Hyslop MSP said:
"This is a huge boost for Scotland's economy which shows the country is still very much open for business as we look to emerge from lockdown. Life sciences has been a cornerstone of our economy for many years and this announcement shows that the sector will continue to drive growth in the future and help in the fight against the pandemic.”
"It also makes it clear that Scotland remains an attractive location for global investors. The fact that hundreds of high-quality research jobs are being created shows that the company recognises the skills there are in the country's workforce.
"This project underlines the importance of a Team Scotland approach to working together to provide the right environment for international businesses to grow along with the benefits to the local communities."
The creation of the new base at Maxim Park, Eurocentral, will see the establishment of the company's third major site of operations in Scotland forming the basis of its global R&D hub. Up to 80% of the healthcare products manufactured by the firm will be for the export market. This includes the USA, Europe, and Japan as well as supplying point of care diagnostics to developing countries that struggle to provide broad testing access due to limitations in laboratory infrastructure.
LumiraDx Chief Executive Ron Zwanziger said:
"Implementing reliable COVID-19 diagnostic testing programs, that provide rapid results with minimum false negatives is critical to safely reopening the economy. We are pleased to contribute to Scotland’s health and economic growth, now and beyond the pandemic."
"We are also delighted to be increasing our footprint in Scotland and expanding the country’s life sciences industry. Next-generation point of care testing technology can help to transform healthcare systems. It’s an exciting undertaking, and we know to do this quickly and to do it well we need the right infrastructure in place and access to incredible talent to drive this development. Scotland has both. We are proud to be investing in the country and its communities.” We are grateful to the Scottish Enterprise for their support through this grant."
Scottish Enterprise interim Chief Executive Linda Hanna said:
"LumiraDx is at the global cutting edge of next generation rapid diagnostic testing and this investment has the potential to be transformative for Scotland’s life sciences sector and wider economy.
"Over the last decade, we and our partners have steadfastly pursued an ambition to simultaneously create wealth whilst promoting health by nurturing a vibrant life sciences sector that thrives on academic excellence, exceptional skills and a strong and supportive business environment.
"It is those strengths that have helped secure LumiraDx’s investment in Scotland and we look forward to working with the company as it goes from strength to strength providing healthcare diagnostic solutions to communities around the world."
LumiraDx was founded in 2014 by a group of entrepreneurs: Ron Zwanziger, our Chairman and Chief Executive Officer; Dave Scott, Ph.D., our Chief Technology Officer; and Jerry McAleer, Ph.D., our Chief Scientist, who have a successful track record in building and scaling diagnostics businesses over three decades, including at companies such as Medisense, Inc., Inverness Medical Technology Inc. and Alere Inc. The company is supported by institutional and strategic investors including the Bill & Melinda Gates Foundation, Morningside Ventures and U.S. Boston Capital Corporation. Based in the UK and supported by its worldwide affiliates to provide access in all major markets, LumiraDx has over 1000 employees worldwide.
LumiraDx develops, manufactures and commercializes an innovative point of care diagnostic Platform. The LumiraDx Platform is designed to deliver lab comparable diagnostic results at the point of care in minutes. It is designed to be affordable and accessible for healthcare providers globally, and to strengthen community-based healthcare.
Further information on LumiraDx and the LumiraDx Platform is available at lumiradx.com.
FOR MORE INFORMATION CONTACT
For company inquiries and interviews contact Tiwa Adebayo (m) +44 7741 144 511 /Media@LumiraDx.com
Scott Macnab / 07500 030 394 / firstname.lastname@example.org